OVA Peptide (257-264) is an MHC Class I (Kb) -restricted OVA polypeptide epitope, an octapeptide derived from ovalbumin presented by Class I MHC molecule H-2Kb.It can be used to stimulate T cell activation and activate the immune response of CD8+ cytotoxic T lymphocytes (CTL) [1-3].
OVA peptide (257-264) (injected intradermally at the base of the tail) combined with anti-CD4-monoclonal antibody increased the number of peptide-specific CTLs and showed a higher therapeutic effect against OVA-expressing tumors in mice[4]. Spleen cells pulsed with OVA peptide (257-264)( 250 μg-1mg) are sensitive to Poria cocos polysaccharide (PCP) [5]. OVA peptide (257-264) can be used as a self-assembled nanovaccine (I-OVA NE), which enhances peptid-specific CD8+T cells and exhibits ova257-264 specific CTL activity and Th1 immune response[6]. Mice anterior chamber inoculation of OVA Peptide (257-264) (250 μg) could induceanterior chamber associated immune deviation (ACAID) as evidenced by an impaired delayed-type hypersensitivity (DTH) response[7].
References:
[1]. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol. 1996 Nov;26(11):2790-9. doi: 10.1002/eji.1830261135. PMID: 8921970.
[2]. Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol. 2000;18:561-92. doi: 10.1146/annurev.immunol.18.1.561. PMID: 10837069.
[3]. Grolleau-Julius A, Harning EK,et,al. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res. 2008 Aug 1;68(15):6341-9. doi: 10.1158/0008-5472.CAN-07-5769. PMID: 18676859; PMCID: PMC2575813.
[4]. Fujinami N, Yoshikawa T, et,al. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep. 2016 Feb 19;5:482-491. doi: 10.1016/j.bbrep.2016.02.010. PMID: 28955856; PMCID: PMC5600353.
[5]. Dong X, Li B, et,al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice. PLoS One. 2021 Jan 7;16(1):e0245207. doi: 10.1371/journal.pone.0245207. PMID: 33411807; PMCID: PMC7790389.
[6]. Yang Y, Ge S, et,al. A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression. Int J Biol Macromol. 2021 Jul
31;183:1891-1902. doi: 10.1016/j.ijbiomac.2021.05.158. Epub 2021 May 27. PMID: 34052270.
[7]. Ren Y, Yang P, et,al. OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation. Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1315-21. doi: 10.1007/s00417-006-0255-0. Epub 2006 Mar 15. PMID: 16538449.
OVA Peptide（257-264）是 OVA 的 I 类 (Kb)-限制性肽表位，由Class I MHC分子H-2Kb递呈的一种来自卵白蛋白的八聚肽。可用来刺激T细胞活化,激活CD8+细胞毒性T淋巴细胞(CTL)的免疫应答[1-3]。
OVA Peptide（257-264）(尾底皮下注射)联合抗CD4单克隆抗体可增加多肽特异性CTL的数量，对小鼠表达OVA的肿瘤有较高的治疗效果[4]。OVA Peptide（257-264）(250 μg-1mg)脉冲脾脏细胞对茯苓多糖(PCP)敏感[5]。OVA Peptide（257-264）可以作为一种自组装纳米疫苗(I-OVA NE)，它可以增强肽特异性CD8+ T细胞，并表现出OVA Peptide（257-264）特异性CTL活性和Th1免疫反应[6]。小鼠前房接种OVA Peptide（257-264）(250 μg)可诱导小鼠前房相关免疫偏差(ACAID)，表现为延迟型超敏反应(DTH)反应受损[7]。